Qyuns Therapeutics Co., Ltd. Class H 2509

The startups are part of a surge of young companies equipped with advanced drug prospects and quickly pivoting to the public markets.

Amidst geopolitical tensions and rising energy prices impacting global markets, Asian equities have experienced fluctuations as investors navigate these uncertainties. In this environment, identifying stocks that may be undervalued involves assessing companies with strong fundamentals and growth potential that are currently priced below their intrinsic value.

In the current landscape, Asian markets are navigating through heightened geopolitical tensions and fluctuating energy prices, contributing to a complex economic environment. Amidst these challenges, identifying undervalued stocks can offer potential opportunities for investors seeking value in a turbulent market. Recognizing stocks trading below their intrinsic value may provide an edge in capitalizing on long-term growth prospects despite short-term uncertainties.

As global markets grapple with AI disruption concerns and shifting economic indicators, the Asian stock markets present a unique landscape of opportunities. In this environment, identifying stocks that are trading below their intrinsic value can be particularly appealing to investors seeking potential growth amid broader market volatility.

Windward Bio and Qyuns Therapeutics announce licensing agreement for WIN027, a highly potent, long-acting bispecific antibody with best-in-disease potential in respiratory and dermatologyWIN027 blocks 2 well-validated and synergistic drivers of inflammation — TSLP and IL‑13 — that play integral roles in respiratory and dermatology diseasesWIN027 deepens the company’s immunology pipeline and is currently in Phase 1 BASEL, Switzerland, Dec. 21, 2025 (GLOBE NEWSWIRE) -- Windward Bio AG, a private,